US 11,712,425 B2
Immunoregulatory role of 3-OH-kynurenamine and uses thereof
Laura Santambrogio, New York City, NY (US)
Assigned to ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, NY (US)
Appl. No. 16/980,204
Filed by ALBERT EINSTEIN COLLEGE OF MEDICINE, Bronx, NY (US)
PCT Filed Mar. 12, 2019, PCT No. PCT/US2019/021731
§ 371(c)(1), (2) Date Sep. 11, 2020,
PCT Pub. No. WO2019/178013, PCT Pub. Date Sep. 19, 2019.
Claims priority of provisional application 62/642,633, filed on Mar. 14, 2018.
Prior Publication US 2021/0008021 A1, Jan. 14, 2021
Int. Cl. A61K 31/198 (2006.01); A61P 37/00 (2006.01); A61K 38/21 (2006.01)
CPC A61K 31/198 (2013.01) [A61K 38/217 (2013.01); A61P 37/00 (2018.01)] 3 Claims
 
1. A method for treating or preventing an autoimmune disease or disorder in a subject in need thereof,
the method comprising administering to the subject 3-OH-kynurenamine in an amount effective to treat or prevent the autoimmune disease or disorder, wherein the autoimmune disease or disorder is psoriasis or nephrotoxic lupus.